Effects of empagliflozin on erythropoiesis in patients with type 2 diabetes: Data from a randomized, placebo‐controlled study-Reference-Cited by-同舟云学术

Effects of empagliflozin on erythropoiesis in patients with type 2 diabetes: Data from a randomized, placebo‐controlled study

Published:2021-08-25 Issue:12 Volume:23 Page:2814-2818
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Thiele Kirsten¹,Rau Matthias¹,Hartmann Niels‐Ulrik K.¹,Möllmann Julia¹,Jankowski Joachim²,Böhm Michael³,Keszei András P.⁴,Marx Nikolaus¹,Lehrke Michael¹

Affiliation:

1. Department of Internal Medicine I University Hospital Aachen, RWTH Aachen University Aachen Germany

2. Institute for Molecular Cardiovascular Research University Hospital Aachen, RWTH Aachen University Aachen Germany

3. Department of Internal Medicine III University Hospital Saarland, Saarland University Homburg Germany

4. Center for Translational & Clinical Research Aachen (CTC‐A) RWTH Aachen University Aachen Germany

Funder

Boehringer Ingelheim

Deutsche Forschungsgemeinschaft

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14517

Reference17 articles.

1. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

2. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

3. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

4. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

5. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of canagliflozin on kidney oxygenation evaluated using blood oxygenation level-dependent MRI in patients with type 2 diabetes;Frontiers in Endocrinology;2024-08-30

2. Effects of sodium–glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes in people with diabetes and advanced chronic kidney disease;Diabetologia;2024-08-29

3. Update on the clinical applications of SGLTis: Insight to benefits beyond hypoglycemic and cardiorenal protection;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2024-07-08

4. Association Between SGLT2 Inhibitor Use and Change in Hemoglobin Among Adults with Diabetes: A Nationwide Cohort Study;Journal of General Internal Medicine;2024-04-09

5. SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits;Cardiovascular Research;2024-03-08